BEHAVOX
16.5.2022 15:05:13 CEST | Business Wire | Press release
Behavox , which provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors, today announced that its academic research paper on artificial intelligence “Continual learning using lattice-free MMI for speech recognition” has been accepted by the International Conference on Acoustics, Speech, and Signal Processing (ICASSP). ICASSP is the world's largest and most comprehensive technical conference focused on signal processing and its applications. Behavox presented this paper in Singapore for IEEE ICASSP 2022 on May 9, 2022.
“Sometimes scientists do research for science’s sake and society is unlikely to see benefits in the near future. In contrast, we pushed science to a new frontier to find a solution to a current problem,” said Behavox CTO Joseph Benjamin. “We are honored to have received recognition from such a prestigious conference and are very proud of our team and the work they did.”
The paper, written by Behavox’s Machine Learning team, addresses challenges of continuously improving speech recognition systems in privacy-preserving settings. This research directly links to Behavox’s R&D approach for providing customers with the best transcription quality in the financial market. In FinTech, the language and the data that Behavox systems have to reliably process rapidly change over time, with the rise of cryptocurrencies and video communications being but two examples.
Consequently, machine learning models must be frequently updated on relevant data. To make such updates possible without undermining data privacy, the model should be able to gradually improve inside secure client environments without access to historical data and data from other customers. This is a challenging problem in machine learning due to catastrophic forgetting, where after improving on a specific type of data, the model starts to perform badly on previously learned data.
The Behavox ICASSP paper contributes to the field of continual learning for speech recognition. Authors propose a novel algorithm that extends and refines the commonly used Learning Without Forgetting (LWF) technique, which relies on a regularization term and forces neural networks to reduce forgetting. More specifically, the authors designed a novel sequence level neural network training loss that can be used instead of conventional point-wise LWF. They demonstrated a significant reduction of forgetting when the neural network is fine-tuned sequentially on various accents and speech styles.
Behavox has found that the use of voice platforms has increased 94 percent year-over-year and that on average almost a third of all workplace communications take place via phone or video conference calls.
This technique has already been successfully applied to its Danish system, where the collaborative work of Behavox linguists, the machine learning team, and a customer allowed Behavox to build its first Danish transcription system that reliably works on banking data.
About Behavox
Behavox provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors.
Through AI-powered analysis of all corporate communications data, including email, instant messaging, voice, and video conferencing platforms, Behavox helps organizations identify illegal, immoral, and malicious behavior in the workplace.
Founded in 2014, Behavox is headquartered in Montreal and has offices in New York City, London, Seattle, Singapore, and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
